Multidrug resistance (MDR) is a serious phenomenon employed by cancer cells which
hampers the success of cancer pharmacotherapy. One of the common mechanisms of MDR …

For the past 30 years, improvements in the survival of patients with osteosarcoma have been
mostly incremental. Despite evidence of genomic instability and a high frequency of …

Osteosarcoma is one of the most common primary tumours of the bone, with a 5‐year
survival rate of less than 20% after the development of metastases. Osteosarcoma is highly …

Histone deacetylases (Hdacs) are conserved enzymes that remove acetyl groups from
lysine side chains in histones and other proteins. Eleven of the 18 Hdacs encoded by the …

There has been increasing evidence that numerous bioactive dietary agents can hamper the
process of carcinogenesis by targeting epigenetic alterations including DNA methylation …

DNA methylation is a mammalian epigenetic mark that participates to define where and
when genes are expressed, both in normal cells and in the context of diseases. Like other …

The regulation of bone formation and detailed mechanisms are still largely elusive, and the
roles of microRNAs in this process have attracted much attention. Recently, a specific …

Epigenetic changes play a significant role in cancer progression, maintenance and therapy
resistance. Generally, epigenetic modifications are reversible, thereby gaining attention for …

In recent, intra-and inter-tumor heterogeneity is seen as one of key factors behind success
and failure of chemotherapy. Incessant use of doxorubicin (DOX) drug is associated with …

Osteosarcoma is a malignant tumor in the bone, which originates from normal osteoblasts or
osteoblast precursors. Normal osteoblasts express estrogen receptor alpha (ERα); however …